A randomized, double-blind comparative clinical study evaluating the impact of an investigational product in managing post-operative inflammation in orthopedic surgeries.

Surgical wounds, especially in co-morbid conditions, pose significant challenges in management. The growing use of multiple medications in healthcare highlights their relevance, yet applying them effectively in surgical wound care is comparable to "separating diamonds from the ore." Despite efforts to unravel wound molecular intricacies and explore the impact of various molecules, a definitive, evidence-based therapy for wounds remains elusive. The recent pandemic has exacerbated healthcare challenges due to limited access to facilities. In addressing clinical challenges, a clear understanding of protease enzymes is essential, offering clinicians better options for selecting appropriate drug regimens.

This study is crucial as effective management of post-operative inflammation in orthopedic surgeries is essential for optimizing patient recovery and reducing complications. Evaluating an investigational test product through rigorous clinical trials can potentially introduce safer and more effective treatment options. Improved inflammation control could lead to shorter hospital stays, decreased healthcare costs, and enhanced patient satisfaction. Addressing these aspects contributes significantly to advancing orthopedic surgical care and patient outcomes. Thus, the aim of the study was to compare the short-term efficacy and tolerability of an oral enzyme supplement (EnMax) with the placebo and similar market product post –operative patients.